-
In the past few years, it has been shown that many drugs are not equally effective for every patient, and this variability is due, at least in part, to genetic differences.
-
Momenta's second generic product candidate is M356, a technology-enabled generic version of Copaxone (glatiramer acetate), a complex drug consisting of a mixture of polypeptide chains. Copaxone is indicated for the reduction of the frequency of relapses
-
The BENEFIT study (BEtaseron in Newly Emerging multiple sclerosis For Initial Treatment), sponsored by Bayer HealthCare, compared Betaseron treatment initiated after a first clinical event with delayed treatment.
-
Biogen Idec Inc. (BIIB.O: Quote, Profile , Research) reported second-quarter earnings that topped expectations on Tuesday, helped by higher sales of its drugs for multiple sclerosis and cancer and a lower tax rate.
-
The MINDSET-01 phase II, double-blind, placebo-controlled trial is designed to evaluate the safety and efficacy of MBP8298 in patients with relapsing-remitting MS.
-
Savitex, an oral spray developed by the drugs company GW Pharmaceuticals, is now unlikely to gain regulatory approval in this country until 2009 despite recently winning full regulatory approval in Canada
-
TRIMESTA (oral estriol), its proprietary therapy for multiple sclerosis (MS), in a multi-center Phase II/III clinical trial for the treatment of women with relapsing-remitting MS.
-
The MS-F204 study, which is conducted under a Special Protocol Assessment (SPA) issued by the Food and Drug Administration (FDA), will evaluate the safety and efficacy of Fampridine-SR in improving walking ability in people with MS.
-
the first patients have been enrolled in MAESTRO-03, its U.S. pivotal phase III clinical trial of MBP8298, a proprietary synthetic peptide for the treatment of multiple sclerosis
-
Under a Pharmaceutical Benefits Scheme ruling, people with MS will miss out on the drug, Tysabri, unless they can pay more than $30,000 a year when it becomes available in Australia in a few months.
-
Since 1987, NORD has administered programs to assist uninsured or under-insured individuals in securing life-saving or life-sustaining medications.
-
There have been no additional reports of a serious brain infection known as progressive multifocal leukoencephalopathy, or PML, among patients taking the multiple-sclerosis drug Tysabri, the drug's makers said Thursday
-
Rituxan cancer drug proved highly effective against multiple sclerosis in a small mid-stage trial, signaling a potentially more effective way of treating the progressive neurological disease.
-
BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), is pleased to announce Dr. Clyde E. Markowitz as the lead investigator in the United States for the Company’s pivotal phase III clinical trial of its lead dru
-
Your guide to using technology to help improve the way
